Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Wednesday, July 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75.
• On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25.

Halozyme Therapeutics Price Performance

HALO opened at $100.67 on Friday. The company has a fifty day simple moving average of $79.11 and a 200 day simple moving average of $72.36. The firm has a market cap of $11.43 billion, a price-to-earnings ratio of 30.05, a PEG ratio of 0.41 and a beta of 0.85. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $104.78. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $91.20.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Measured Wealth Private Client Group LLC grew its position in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Abel Hall LLC raised its position in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 129 shares in the last quarter. StoneX Group Inc. raised its position in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 132 shares in the last quarter. Moran Wealth Management LLC lifted its stake in Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares during the last quarter. Finally, Twin Capital Management Inc. lifted its stake in Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 161 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.